Evidence map›Paper›PMID 36847234›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2023

A New

Alessandra Terracciano, Margherita Lucia De Bernardi, Roberto Novizio, Davide De Brasi, Achille Iolascon, Matteo Della Monica, Francesco Scavuzzo, Domenico Serino, Antonio Novelli, Carmelo Piscopo

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Alessandra TerraccianoTranslational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Margherita Lucia De BernardiDepartment of Molecular Medicine and Medical Biotechnology, University Federico II, Naples, Italy.
Roberto NovizioEndocrinology Unit, Cardarelli Hospital, Naples, Italy.ORCID 0000-0001-5641-6847
Davide De BrasiEndocrinology Unit, Cardarelli Hospital, Naples, Italy.
Achille IolasconDepartment of Molecular Medicine and Medical Biotechnology, University Federico II, Naples, Italy.
Matteo Della MonicaMedical and Laboratory Genetic Unit, Cardarelli Hospital, Naples, Italy.
Francesco ScavuzzoEndocrinology Unit, Cardarelli Hospital, Naples, Italy.
Domenico SerinoEndocrinology Unit, Cardarelli Hospital, Naples, Italy.
Antonio NovelliTranslational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Carmelo PiscopoMedical and Laboratory Genetic Unit, Cardarelli Hospital, Naples, Italy.
Fatebenefratelli Hospital · ITBambino Gesù Children's Hospital · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundX-linked hypophosphatemia is the most prevalent form of heritable rickets, characterized by an X-linked dominant inheritance pattern. The genetic basis of X-linked hypophosphatemia is a loss-of-function mutation in the PHEX gene (Phosphate regulating gene with Homology to Endopeptidases on the X chromosome), which leads to an enhanced production of phosphaturic hormone FGF23. X-linked hypophosphatemia causes rickets in children and osteomalacia in adults. Clinical manifestations are numerous and variable, including slowdown in growth, swing-through gait and progressive tibial bowing, related to skeletal and extraskeletal actions of FGF23. PHEX gene spans over 220 kb and consists of 22 exons. To date, hereditary and sporadic mutations are known (missense, nonsense, deletions and splice site mutations). CASE PRESENTATION: Herein, we describe a male patient carrying a novel de novo mosaic nonsense mutation c.2176G>T (p.Glu726Ter) located in exon 22 of PHEX gene.

conclusionWe highlight this new mutation among possible causative of X-linked hypophosphatemia and suggest that mosaicism of PHEX mutations is not so uncommon and should be excluded in diagnostic workflow of heritable rickets both in male and female patients.

Indexed as

Familial Hypophosphatemic RicketsRickets, HypophosphatemicAdultChildExonsFemaleHumansMaleMutationPHEX Phosphate Regulating Neutral EndopeptidasePHEX Phosphate Regulating Neutral EndopeptidasePHEX protein, humandominant X-linked inheritanceendopeptidaseFGF23phosphate regulating genevitamin D resistant ricketsX-linked hypophosphatemia

Identifiers

PMID36847234
PMCPMC10518859
OpenAlexW4322495894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.